期刊文献+

人白细胞介素37的二级结构及B细胞表位预测 被引量:4

Prediction of secondary structure and B-cell epitope of human IL-37
下载PDF
导出
摘要 目的:预测人IL-37b蛋白质的二级结构及B细胞抗原表位。方法:以IL-37b蛋白质的氨基酸序列为基础,应用ProScale、Bcepred服务器,分析人IL-37b亲水性、柔韧性、可及性和抗原性指数,并结合二级结构特征,预测IL-37b的B细胞表位。结果:IL-37b的二级结构主要由β折叠(31.65%)、无规则卷曲(52.75%)、α螺旋(8.26%)和β转角(7.34%)组成。其B细胞表位可能位于第21-27、34-75、175-192和213-215氨基酸区段。结论:此结果将有助于确定IL-37b的B细胞表位,为研制人IL-37单克隆抗体提供了理论依据。 Objective:To predict the secondary structure and B-cell epitope of human IL-37.Methods:Based on IL-37b ami-no acid sequence, the secondary structure was predicted by SOPMA; hydrophilicity, flexibility, accessibility index were predicted by software of ProScale, Bcepred, respectively.Combined the results according to these methods , the B cell epitopes of IL-37b were pre-dicted.Results: The second structure of IL-37b contained extended strand (31.65%), random coil (52.75%), alpha helix (8.26%), beta turn (7.34%) and the most possible epitopes of IL-37b were located in or adjacent to amino acid 21-27, 34-75, 175-192 , 213-215 .Conclusion:These results will be helpful for the estimate of the epitopes and provide a theory basis for developing mon -oclonal antibodies against human IL-37.
出处 《中国免疫学杂志》 CAS CSCD 北大核心 2014年第5期648-650,653,共4页 Chinese Journal of Immunology
基金 浙江省自然科学基金(LY13H090014) 浙江省教育厅科研项目(Y201327689) 宁波大学学科项目(XKL11D2112) 宁波市科技计划项目(2013C50054) 宁波大学创新性开放实验项目(cxxkf2013-016)资助
关键词 IL-37 B细胞表位 二级结构 IL-37 B cell epitope Secondary structure
  • 相关文献

参考文献17

  • 1Kumar S, McDonnell PC, Lehr R,et al. Identification and initial characterization of four novel members of the interleukin-1 family [J]. J Biol Cherr, 2000, 275(14): 10308-10314. 被引量:1
  • 2Nold MF, Nold-Petry CA, Zepp JA,et al. IL-37 is a fundamental inhibitor of innate immunity [ J ]. Nat Immunol, 2010, 11( 11 ) : 1014-1022. 被引量:1
  • 3Buffer P, Azam T, Gamboni-Robertson F,et al. A complex of the 1L-1 homologue IL-1FTb and IL-18-binding protein reduces IL-18 activity [ J]. Proc Natl Acad Sci USA, 2002, 99 (21): 13723-13728. 被引量:1
  • 4Buraschi D, Lucchesi D, Hainzl S,et al. IL-37: a new anti-in- ffammatory cytokine of the IL-1 family [ J ]. Eur Cytokine Netw, 2011, 22(3) : 127-147. 被引量:1
  • 5Shanna S, Kulk N, Nold MF,et al. The IL-1 family member 7b translocates to the nucleus and down-regulates proinffammatm7 cy- tokines[J]. J Immunol, 2008, 180(8) : 5477-5482. 被引量:1
  • 6Pan G, Risser P, Mao W,et al. IL-1 H, an interleukin l-related protein that binds IL-18 receptor/IL-1Rrp [ J ]. Cytokine, 2001, 13(1): 1-7. 被引量:1
  • 7Kumar S, Hanning CR, Brigham-Burke MR, et-al7 Tnterleukin- 1FTB (IL-I H4/IL-1 F7 ) is processed by caspase-1 and mature IL- IFTB binds to the IL-18 receptor but does not induce IFN-gamma produetion[J]. Cytokine, 2002, 18(2) : 61-71. 被引量:1
  • 8Song L, Qiu F, Fan Y,et al. Glucocorticoid regulates interleukin- 37 in systemic lupus erythematosus[ J]. J Clin Immunol, 2013, 33(1): 111-117. 被引量:1
  • 9Li C, Ji H, Cai Y,et al. Serum Interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment [ J ]. J Interferon Cytokine Res, 2013, 33 ( 10 ) : 612-618. 被引量:1
  • 10Imaeda H, Takahashi K, Fujimoto T,et al. Epithelial expression of interleukin-37b in inflammatory bowel disease[ J]. Clin Exp Immunol, 2013, 172(3) : 410-416. 被引量:1

同被引文献58

  • 1吴玉章,朱锡华.一种病毒蛋白B细胞表位预测方法的建立[J].科学通报,1994,39(24):2275-2279. 被引量:82
  • 2Bruni L, Barrionuevo-Rosas L, Albero G, et al. ICO Information Centre on HPV and Cancer (HPV Information Centre ). Human papillomavirus and related diseases in the world. Summary report 2015 - 12 - 23. (2015 - 12 - 23 ) [ 2015 - 12 - 25 ]. http ://www. hpvcentre, net/statistics/reports/XWX, pdf. 被引量:1
  • 3Hassan S W, Waheed M T, Miller M, et al. Expression of HPV-16 L1 capsomeres with glutathione-S-transferase as a fusion protein in tobacco plastids: an approach for a capsomere-based HPV vaccine [ J ]. Hum Vaccine Immunother, 2014, 10 (10) : 2975 - 2982. 被引量:1
  • 4NO authors listed. Human papillomavirus vaccines: WHO position paper, October 2014-Recommendations [ J ]. Vaccine, 2015, 33(36) : 4383 -4384. 被引量:1
  • 5Parkin D M. Global cancer statistics in the year 2000 [ J ]. Lancet Oncol, 2001, 2(9): 533-543. 被引量:1
  • 6Schiller J T, Castellsagu6 X, Garland S M. A review of clinical trials of human papillomavirus prophylactic vaccines[J]. Vaccine, 2012, 30:F123 - F138. 被引量:1
  • 7Herrere R, Gonzalez P, Markowitz L E. Present status of human papillomavirus vaccine development and implementation [ J/OL ]. Lancet Oncol, 2015, 16(5) : e206 - e216. doi: 10. 1016/S1470 - 2045( 14)70481 -4. 被引量:1
  • 8Schiller J T, Mttller M. Next generation prophylactic human papillomavirus vaceines[J/OL]. Lancet Oncol, 2015, 16(5): e217- e225. doi: 10. 1016/S1470 -2045( 14)71179 -9. 被引量:1
  • 9Guan J, Bywaters S M, Brendle S A, et al. Structural comparison of four different antibodies interacting with human papillomavims 16 and mechanisms of neutralization [ J]. Virology, 2015, 483 : 253 - 263. 被引量:1
  • 10Wang X M, Cook J C, Lee J C, et aL Human papiUomavims type 6 virus-like particles present overlapping yet distinct conformational epitopes[J]. J Gen Virol, 2003, 84(6) : 1493 -1497. 被引量:1

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部